Literature DB >> 28787408

First approval in sight for Novartis' CAR-T therapy after panel vote.

Cormac Sheridan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28787408     DOI: 10.1038/nbt0817-691

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  CAR-T death strikes Kite.

Authors: 
Journal:  Nat Biotechnol       Date:  2017-06-07       Impact factor: 54.908

2.  CAR-T cells forge ahead, Novartis reorganizes.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2016-11-08       Impact factor: 54.908

  2 in total
  14 in total

1.  Radioactive drugs emerge from the shadows to storm the market.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2018-12-06       Impact factor: 54.908

2.  Epic $12 billion deal and FDA's approval raise CAR-T to new heights.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-10-11       Impact factor: 54.908

3.  Bugs as Cancer Drugs: Challenges and Opportunities.

Authors:  Phillip J Daschner; Avraham Rasooly; Jeffrey D White
Journal:  Mol Cell Biol       Date:  2019-07-16       Impact factor: 4.272

Review 4.  Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Authors:  Stefan Kiesgen; Leonardo Chicaybam; Navin K Chintala; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2017-10-26       Impact factor: 15.609

5.  T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.

Authors:  Stefanie Lesch; Viktoria Blumenberg; Stefan Stoiber; Adrian Gottschlich; Justyna Ogonek; Bruno L Cadilha; Zahra Dantes; Felicitas Rataj; Klara Dorman; Johannes Lutz; Clara H Karches; Constanze Heise; Mathias Kurzay; Benjamin M Larimer; Simon Grassmann; Moritz Rapp; Alessia Nottebrock; Stephan Kruger; Nicholas Tokarew; Philipp Metzger; Christine Hoerth; Mohamed-Reda Benmebarek; Dario Dhoqina; Ruth Grünmeier; Matthias Seifert; Arman Oener; Öykü Umut; Sandy Joaquina; Lene Vimeux; Thi Tran; Thomas Hank; Taisuke Baba; Duc Huynh; Remco T A Megens; Klaus-Peter Janssen; Martin Jastroch; Daniel Lamp; Svenja Ruehland; Mauro Di Pilato; Jasper N Pruessmann; Moritz Thomas; Carsten Marr; Steffen Ormanns; Anna Reischer; Michael Hristov; Eric Tartour; Emmanuel Donnadieu; Simon Rothenfusser; Peter Duewell; Lars M König; Max Schnurr; Marion Subklewe; Andrew S Liss; Niels Halama; Maximilian Reichert; Thorsten R Mempel; Stefan Endres; Sebastian Kobold
Journal:  Nat Biomed Eng       Date:  2021-06-03       Impact factor: 25.671

6.  A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology.

Authors:  Hao-Kang Li; Ching-Wen Hsiao; Sen-Han Yang; Hsiu-Ping Yang; Tai-Sheng Wu; Chia-Yun Lee; Yan-Liang Lin; Janet Pan; Zih-Fei Cheng; Yan-Da Lai; Shih-Chia Hsiao; Sai-Wen Tang
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 7.  Engineering adeno-associated virus vectors for gene therapy.

Authors:  Chengwen Li; R Jude Samulski
Journal:  Nat Rev Genet       Date:  2020-02-10       Impact factor: 59.581

8.  Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.

Authors:  Zhongzhen Yi; Brooke L Prinzing; Felicia Cao; Stephen Gottschalk; Giedre Krenciute
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-02       Impact factor: 6.698

Review 9.  Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation.

Authors:  Yating Sun; Yarong Zhao; Xiuting Zhao; Robert J Lee; Lesheng Teng; Chenguang Zhou
Journal:  Molecules       Date:  2017-10-13       Impact factor: 4.411

Review 10.  Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.

Authors:  Chunyi Shen; Zhen Zhang; Yi Zhang
Journal:  Biomed Res Int       Date:  2020-10-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.